|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gaedcke J, Grade M, Camps J, Søkilde R,
Kaczkowski B, Schetter AJ, Difilippantonio MJ, Harris CC, Ghadimi
BM, Møller S, et al: The rectal cancer microRNAome - microRNA
expression in rectal cancer and matched normal mucosa. Clin Cancer
Res. 18:4919–4930. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: the impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang S, Cui Y, Weng Z, Gong X, Chen M and
Zhong B: Changes on the disease pattern of primary colorectal
cancers in Southern China: a retrospective study of 20 years. Int J
Colorectal Dis. 24:943–949. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Speetjens FM, Zeestraten EC, Kuppen PJ,
Melief CJ and van der Burg SH: Colorectal cancer vaccines in
clinical trials. Expert Rev Vaccines. 10:899–921. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Diep CB, Thorstensen L, Meling GI,
Skovlund E, Rognum TO and Lothe RA: Genetic tumor markers with
prognostic impact in Dukes’ stages B and C colorectal cancer
patients. J Clin Oncol. 21:820–829. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Walther A, Johnstone E, Swanton C, Midgley
R, Tomlinson I and Kerr D: Genetic prognostic and predictive
markers in colorectal cancer. Nat Rev Cancer. 9:489–499. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Roth AD, Tejpar S, Delorenzi M, Yan P,
Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C,
et al: Prognostic role of KRAS and BRAF in stage II and III
resected colon cancer: results of the translational study on the
PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 28:466–474.
2010. View Article : Google Scholar
|
|
10
|
Rajagopalan H, Bardelli A, Lengauer C,
Kinzler KW, Vogelstein B and Velculescu VE: Tumorigenesis: RAF/RAS
oncogenes and mismatch-repair status. Nature. 418:9342002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
French AJ, Sargent DJ, Burgart LJ, Foster
NR, Kabat BF, Goldberg R, Shepherd L, Windschitl HE and Thibodeau
SN: Prognostic significance of defective mismatch repair and BRAF
V600E in patients with colon cancer. Clin Cancer Res. 14:3408–3415.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Anastas JN and Moon RT: WNT signalling
pathways as therapeutic targets in cancer. Nat Rev Cancer.
13:11–26. 2013. View
Article : Google Scholar
|
|
13
|
Ishikawa T, Shimizu D, Kito A, Ota I,
Sasaki T, Tanabe M, Yamada A, Arioka H, Shimizu S, Wakasugi J, et
al: Breast cancer manifested by hematologic disorders. J Thorac
Dis. 4:650–654. 2012.PubMed/NCBI
|
|
14
|
Emami KH, Brown LG, Pitts TE, Sun X,
Vessella RL and Corey E: Nemo-like kinase induces apoptosis and
inhibits androgen receptor signaling in prostate cancer cells.
Prostate. 69:1481–1492. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jung KH, Kim JK, Noh JH, Eun JW, Bae HJ,
Xie HJ, Ahn YM, Park WS, Lee JY and Nam SW: Targeted disruption of
Nemo-like kinase inhibits tumor cell growth by simultaneous
suppression of cyclin D1 and CDK2 in human hepatocellular
carcinoma. J Cell Biochem. 110:687–696. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cui G, Li Z, Shao B, Zhao L, Zhou Y, Lu T,
Wang J, Shi X, Wang J, Zuo G, et al: Clinical and biological
significance of nemo-like kinase expression in glioma. J Clin
Neurosci. 18:271–275. 2011. View Article : Google Scholar
|
|
17
|
Wang S, Wu X, Chen Y, Zhang J, Ding J,
Zhou Y, He S, Tan Y, Qiang F, Bai J, et al: Prognostic and
predictive role of JWA and XRCC1 expressions in gastric cancer.
Clin Cancer Res. 18:2987–2996. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Weichert W, Röske A, Gekeler V, Beckers T,
Ebert MP, Pross M, Dietel M, Denkert C and Röcken C: Association of
patterns of class I histone deacetylase expression with patient
prognosis in gastric cancer: a retrospective analysis. Lancet
Oncol. 9:139–148. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ishitani T and Ishitani S: Nemo-like
kinase, a multifaceted cell signaling regulator. Cell Signal.
25:190–197. 2013. View Article : Google Scholar
|
|
20
|
Ota S, Ishitani S, Shimizu N, Matsumoto K,
Itoh M and Ishitani T: NLK positively regulates Wnt/β-catenin
signalling by phosphorylating LEF1 in neural progenitor cells. EMBO
J. 31:1904–1915. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ishitani T: Context-dependent dual and
opposite roles of nemo-like kinase in the Wnt/β-catenin signaling.
Cell Cycle. 11:1743–1745. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yasuda J, Yokoo H, Yamada T, Kitabayashi
I, Sekiya T and Ichikawa H: Nemo-like kinase suppresses a wide
range of transcription factors, including nuclear factor-κB. Cancer
Sci. 95:52–57. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li M, Zhang S, Wang Z, Zhang B, Wu X, Weng
H, Ding Q, Tan Z, Zhang N, Mu J, et al: Prognostic significance of
nemo-like kinase (NLK) expression in patients with gallbladder
cancer. Tumour Biol. 34:3995–4000. 2013. View Article : Google Scholar : PubMed/NCBI
|
